New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:19 EDTMDVN, ALPMYMedivation, Astellas Pharma submit sNDA for XTANDI
Astellas Pharma (ALPMY) and Medivation (MDVN) announced the submission of a supplemental New Drug Application, or sNDA, to the FDA seeking approval of XTANDI capsules for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-na´ve mCRPC patients. The marketing authorization application is expected to be submitted to the European Medicines Agency later this year.
News For MDVN;ALPMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 17, 2015
12:53 EDTALPMY, MDVNMedivation, Astellas report enzalutamide study met primary endpoint
Subscribe for More Information
May 15, 2015
07:35 EDTMDVNMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
May 14, 2015
07:07 EDTMDVNMedivation to present data in TNBC at ASCO
Medivation announced that the following abstract will be presented during an oral presentation at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting on June 1, in Chicago: Results from a phase 2 study of enzalutamide, an androgen receptor, or AR, inhibitor, in advanced AR+ triple-negative breast cancer, or TNBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use